The Food and Drug Administration today released a final rule regulating certain protein products, such as insulin, as biological products rather than drugs effective March 23. Authorized by the Biologics Price Competition and Innovation Act of 2009, the change will allow new insulin products, and certain other protein products, to apply for marketing approval through the abbreviated pathway for biosimilar or interchangeable products in an effort to increase market competition and lower prices. For more on the change, see the FDA FAQs for health care providers and patients

In other news, FDA today released a table of gene-drug interactions based on FDA labeling and other scientific evidence, which it plans to update periodically to aid prescribers. 
 

Related News Articles

Headline
President Biden today submitted to Congress his discretionary budget request for fiscal year 2022. The budget request, which is not binding, proposes $1.5…
Headline
The Centers for Medicare & Medicaid Services Friday released a toolkit for qualified health plans applying for plan year 2022 certification, and…
Headline
New information sharing requirements for health information technology take effect April 5 under an interim final rule released last year by the Office of the…
Headline
The Department of Homeland Security yesterday formally removed its public charge rule from the Code of Federal Regulations. The Biden administration this…
Headline
AHA today urged the Department of Health and Human Services’ Office for Civil Rights to take a holistic approach as it deliberates changes to the HIPAA Privacy…
Headline
The House and Senate today passed a concurrent budget resolution giving Congress the option to use fast-track procedures to pass the president’s $1.9 trillion…